Peptides DB
Research-centric peptide and protocol reference hub

Evuzamitide record · updated 18h ago

Healing & recoveryInflammation & immuneGrade A · human clinicalResearch use only
All 14 studiesJump to the evidenceCompare
What is Evuzamitide used for?

Evuzamitide is a peptide-based therapeutic agent that was developed using artificial intelligence methodologies. Its primary aim is to exploit the unique properties of peptides for various therapeutic applications, although the specific mechanisms of action are still under investigation. Current research suggests that Evuzamitide may interact with multiple biological pathways, but detailed studies elucidating these interactions are ongoing.

Primarily researched for · Healing & recovery

Development stage

where Evuzamitide sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 128 registered trials. It describes the research record, not a recommendation.

Identity
NameEvuzamitide
Chain length—
Molecular weight—
Formula—
Structure type—
ClassImmune
Research levelLimited Research
Discovered byThe Librarian · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 20, 2026. How this works →
Research stats
Total studies14
Human / animal / cellular8 / 0 / 1
Highest trial phase—
Years covered2026
Latest study28d ago
Publication history
20262026
Research funding
2 NIH projects · $1.4M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

14 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.
FindingOverall sensitivity was 94% (95% CI, 85%-98%; P < 0.001).
Human2026Full text read0.90
&lt;sup&gt;124&lt;/sup&gt;Iodine Evuzamitide Positron Emission Tomography in Patients with Established or Suspected Cardiac Amyloidosis.
FindingMean LV/blood pool standardized uptake value ratio (SUVRmean) was 1.89 ±0.29 in patients with CA and 0.91 ±0.15 in patients without CA, p<0.001.
Human2026Full text read0.90
Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis.
FindingSummary sensitivity of 0.91 (95% CI 0.83-0.96), n=577.
review2026Full text read0.90
Delivering the blueprint: Advances and challenges in mRNA therapeutics for the respiratory system.
TakeawayAdvancements in mRNA-LNP therapeutics for pulmonary disorders face significant challenges, particularly in effective delivery and safety, necessitating further research and validation.
review2026Full text read0.70
Patient and clinician experiences of language barriers in Qatar's multilingual public mental health care: a qualitative study.
TakeawayLanguage barriers significantly challenge mental health care delivery in Qatar, highlighting the need for professional interpreters and language-concordant care.
Human2026Full text read0.80
AI-assisted MALDI-TOF MS for identifying carbapenem resistance in clinical &lt;i&gt;Acinetobacter baumannii&lt;/i&gt; isolates.
FindingAccuracy of 96.36% in distinguishing CRAB from CSAB.
Human2026Full text read0.80
Utero-placental calcium and magnesium ion channels: A systematic review of obstetric implications of their alterations.
FindingNot reported in abstract.
review2026Full text read0.70
Supporting change in a complex reality: a qualitative study of specialist nurses' perceptions of counselling patients at risk of type 2 diabetes.
TakeawaySpecialist nurses face significant barriers in providing effective dietary counselling for diabetes prevention, highlighting the need for better organizational support and cultural competence training.
Human2026Full text read0.80
Mimic antibodies: leveraging ligand mimicry for epitope-targeted antibody discovery.
Finding11 of 31 candidates bound the IL-18RA D3 domain, with eight achieving sub-nanomolar affinities.
In vitro2026Full text read0.80
Training and supervision of lay mental health workers in community-based interventions in East Africa: a scoping review.
FindingNot reported in abstract.
review2026Full text read0.70
Early and mature &lt;i&gt;Achromobacter xylosoxidans&lt;/i&gt; biofilm in cystic fibrosis and non-cystic fibrosis isolates: dynamics and response to clinically relevant antibiotics.
FindingNot reported in abstract.
Human2026Full text read0.80
Longitudinal symptom dynamics in postoperative patients with liver cancer: A cross-lagged panel network analysis.
FindingJaundice predicted vomiting (OR = 1.94, 95% CI [1.70, 2.14]) from T1 to T2.
Human2026Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Evuzamitide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Evuzamitide is discussed should be drawn from it.